Computational approach shows that the occluded state in GLUT transporters is equivalent to the transition state of soluble enzymes and this has the highest affinity for the substrate sugar.

Dysfunctionaladipose tissue puts obese and type 2 diabetic patients at higher risk.

mRNA profiling alone provides an incomplete picture of molecular aging and examination of changes in proteins is essential to understand aging processes that are not transcriptionally regulated.

Animal studies of fatty liver disease over-estimate the benefit of drugs due to publication bias and are confounded by off-target weight loss, illustrating the challenge of successful translational across species.

Anti-asprosin monoclonal antibodies, a promising pharmacotherapy for the treatment of metabolic syndrome-associated hyperglycemia, obesity, and dyslipidemia.

Zebrafish insulin mutants serve as an innovative platform to identify novel mechanisms regulating glucose homeostasis.

In lung adenocarcinoma, deleting one glucose transporter, whether it is Glut1 or Glut3 is insufficient, whereas their dual deletion reduces tumor growth.

An unbiased approach unveils a non-canonical substrate of the known transporters, highlighting the mechanism behind the use of D-serine as a kidney biomarker.

Human metabolism-focused screens reveal clinically promising interventional strategies and repurposing targets to treat COVID-19.

Monounsaturated fatty acids protect against DKD by enhancing membrane fluidity and decreasing ER lipid bilayer stress in renal proximal tubules.